Last reviewed · How we verify
Amlodipine (Norvasc)
Amlodipine blocks calcium channels in vascular smooth muscle and cardiac tissue, causing vasodilation and reduced blood pressure.
Amlodipine blocks calcium channels in vascular smooth muscle and cardiac tissue, causing vasodilation and reduced blood pressure. Used for Hypertension, Angina pectoris (chronic stable angina and vasospastic angina).
At a glance
| Generic name | Amlodipine (Norvasc) |
|---|---|
| Sponsor | Bayer |
| Drug class | Calcium channel blocker (dihydropyridine) |
| Target | L-type voltage-gated calcium channel |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Amlodipine is a dihydropyridine calcium channel blocker that selectively inhibits L-type calcium channels in the vasculature and heart. By preventing calcium influx into smooth muscle cells, it reduces vascular tone and peripheral resistance, leading to vasodilation and decreased blood pressure. It also has mild negative inotropic effects and reduces myocardial oxygen demand.
Approved indications
- Hypertension
- Angina pectoris (chronic stable angina and vasospastic angina)
Common side effects
- Peripheral edema
- Headache
- Flushing
- Fatigue
- Dizziness
- Palpitations
Key clinical trials
- Optimal Blood Pressure for the prevenTIon of Major vAscuLar Events in Patients With DIABETES Mellitus (OPTIMAL-DIABETES) (NA)
- Bioequivalence Study of Sacubitril Alisartan Amlodipine Tablets (PHASE1)
- OPtimizing Technology to Improve Medication Adherence and BP Control (OPTIMA-BP) (NA)
- Triple Antihypertensive Medication After Intracerebral Hemorrhage for Blood Pressure Control (NA)
- Mortality Control Program for Economically Productive Age Group in Tribal Area of Melghat. (PHASE4)
- Sympathetic Mechanisms in Obesity-Crossover Design (PHASE1, PHASE2)
- Alpelisib/iNOS Inhibitor/Nab-paclitaxel in Patients With HER2 Negative Metaplastic Breast Cancer (MpBC) (PHASE2)
- Study to Evaluate the Efficacy and Safety of TEL/AML/CTD in Elderly Patients With Essential Hypertension (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Amlodipine (Norvasc) CI brief — competitive landscape report
- Amlodipine (Norvasc) updates RSS · CI watch RSS
- Bayer portfolio CI